Topical antiviral formulations
The disclosure provides novel topical antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.
1. A topical pharmaceutical composition comprising
a therapeutically effective amount of antiviral compound acyclovir; and
a therapeutically effective amount of 2-deoxy-D-glucose;
wherein the composition comprises a molar ratio of acyclovir to 2-deoxy-D-glucose in a range from about 1:1 to about 18.2:1; and wherein the composition comprises acyclovir in a wt % range of from about 3 wt % to about 5 wt %, and 2-deoxy-D-glucose in a wt % range of about 0.1 wt % to about 0.2 wt %.
2. The composition of claim 1 in a form selected from a lip-balm, stick, cream or ointment.
3. The composition of claim 2 in a lip-balm form.
4. The composition of claim 3 , further comprising one or more polyethylene glycols.
5. The composition of claim 4 , further comprising one or more sweeteners or flavorings.
6. The composition of claim 5 wherein the sweetener is stevioside.
7. The composition of claim 5 wherein the flavoring is spearmint oil.
8. The composition of claim 1 wherein the topical composition comprises about 5 wt % of acyclovir and about 0.2 wt % of 2-deoxy-D-glucose.
9. A method of treating an HSV-1 herpes viral infection of the skin or mucosa of a patient in need thereof comprising topically administering to the skin or mucosa a pharmaceutical composition comprising
a therapeutically effective amount of antiviral compound acyclovir, and
a therapeutically effective amount of 2-deoxy-D-glucose;
wherein the composition comprises a molar ratio of antiviral compound to 2-deoxy-D-glucose in a range from about 1:1 to about 18.2:1; and wherein the composition comprises acyclovir in a wt % range of from about 3 wt % to about 5 wt %, and 2-deoxy-D-glucose in a wt % range of about 0.1 wt % to about 0.2 wt %.
10. The method of claim 9 , wherein the topical composition is in a form selected from a lip-balm, stick, cream or ointment.
11. The method of claim 10 , wherein the topical composition is in a lip-balm form.
12. The method of claim 11 , wherein the topical composition further comprises one or more polyethylene glycols.
13. The method of claim 11 , wherein the topical composition further comprises one or more sweeteners or flavorings.
14. The method of claim 13 , wherein the sweetener is stevioside.
15. The method of claim 13 , wherein the flavoring is spearmint oil.
16. The method of claim 9 , wherein the topical composition comprises about 5 wt % of acyclovir and about 0.2 wt % of 2-deoxy-D-glucose.
17. The method of claim 9 wherein the treatment is for latent infection of herpes simplex type 1 infection.
18. A method of reducing the duration of an HSV-1 herpes viral infection outbreak of the skin or mucosa of a mammal in need thereof comprising administering to the skin or mucosa a pharmaceutical composition comprising
a therapeutically effective amount of antiviral compound acyclovir, and
a therapeutically effective amount of 2-deoxy-D-glucose;
wherein the composition comprises a molar ratio of antiviral compound to 2-deoxy-D-glucose in a range from about 1:1 to about 18.2:1; and wherein the composition comprises acyclovir in a wt % range of from about 3 wt % to about 5 wt %, and 2-deoxy-D-glucose in a wt % range of about 0.1 wt % to about 0.2 wt %.
19. The method of claim 18 , wherein the antiviral compound is acyclovir.
20. The method of claim 18 wherein the treatment is for latent infection of herpes simplex type 1 infection.
21. The method of claim 17 wherein the infection is an orofacial herpes infection.
22. The method of claim 18 wherein the infection is an orofacial herpes infection.
23. The method of claim 20 wherein the infection is an orofacial herpes infection.
24. The method of claim 18 wherein the topical composition comprises about 5 wt % of acyclovir and about 0.2 wt % of 2-deoxy-D-glucose.